Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
Investing.com - Cantor Fitzgerald has reiterated its Overweight rating and $16.00 price target on Solid Biosciences (NASDAQ:SLDB), maintaining its positive outlook on the company’s Duchenne muscular dystrophy (DMD) program. Currently trading at $5.12, the stock sits well below the analyst consensus target range of $10-20, with InvestingPro data showing strong analyst support through multiple upward earnings revisions for the upcoming period.
The firm highlighted that Solid Biosciences’ DMD program uses a novel capsid that efficiently targets muscle tissue and cardiomyocytes while reducing liver uptake, enabling lower dosing requirements. Early data has demonstrated either stability or improvements across key liver markers in patients receiving treatment. According to InvestingPro analysis, the company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 9.34, providing runway for continued program development.
Solid Biosciences’ treatment regimen includes only prophylactic glucocorticoids, distinguishing it from other approaches in the space. On August 12, 2025, the company reported that 15 patients had been dosed in its Phase 1/2 trial without treatment-emergent serious adverse events or hospitalizations.
The company reported only one Grade 1 Adverse Event of Special Interest, involving liver enzyme elevation during steroid taper, which resolved without clinical manifestation. This safety profile supports the company’s approach to DMD treatment.
Cantor Fitzgerald also noted that Solid Biosciences’ SGT-003 contains approximately 80% full capsids, suggesting that reducing empty capsid levels could help make the dose more potent without unnecessarily increasing viral load. With the next earnings report due on November 7, investors can access comprehensive analysis and additional insights through InvestingPro’s detailed research reports, which cover over 1,400 US stocks including deep-dive analysis of Solid Biosciences’ development pipeline and financial metrics.
In other recent news, Solid Biosciences has received Fast Track designation from the U.S. Food and Drug Administration for its gene therapy candidate SGT-501, which targets catecholaminergic polymorphic ventricular tachycardia (CPVT). This designation allows for more frequent interactions with the FDA and potential eligibility for priority review. JMP Securities has reiterated its Market Outperform rating on Solid Biosciences, maintaining a price target of $15.00, highlighting the company’s progress in its Duchenne muscular dystrophy (DMD) program. The firm noted that Solid Biosciences has dosed 15 DMD patients ahead of schedule and plans to meet with the FDA in the fourth quarter of 2025 to discuss regulatory pathways for its SGT-003 therapy. In addition, Cantor Fitzgerald has reiterated an Overweight rating with a price target of $16.00. Solid Biosciences is also advancing its gene therapy programs for multiple conditions, including Friedreich’s Ataxia and CPVT, leveraging specialized capsids and manufacturing capabilities. The company’s focus on the larger AAV-naive DMD patient population has been cited as a positive factor for its outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.